ARS Pharmaceuticals(US:SPRY) GlobeNewswire News Room·2024-10-24 12:30Core Insights - ARS Pharmaceuticals is presenting seven abstracts at the 2024 ACAAI Annual Scientific Meeting, focusing on intranasal epinephrine administration and its implications for treating severe allergic reactions [1][2] Group 1: Company Overview - ARS Pharmaceuticals is a biopharmaceutical company dedicated to protecting at-risk patients from severe allergic reactions that could lead to anaphylaxis [11] - The company has developed neffy®, the first and only needle-free treatment for Type I allergic reactions, including anaphylaxis, for patients weighing 30 kg or more [2][7] Group 2: Research and Development - The research presented at the ACAAI meeting includes studies on cardiovascular safety, real-world administration data in pediatric patients, and the efficacy of intranasal epinephrine [1][2] - Key studies include the cardiovascular safety of intramuscular versus intranasal epinephrine, blood pressure and pulse rate changes during allergic reactions, and pharmacokinetic profiles among different epinephrine products [3][4][5] Group 3: Market Context - Approximately 40 million people in the U.S. experience Type I allergic reactions, but only 3.3 million have an active epinephrine auto-injector prescription, with only half consistently carrying it [5] - The limitations of current epinephrine auto-injectors, such as fear of needles and lack of portability, highlight the potential market for neffy® [4][5]